Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SERCA 2a gene therapy - Theragene Pharmaceuticals

Drug Profile

SERCA 2a gene therapy - Theragene Pharmaceuticals

Alternative Names: AAV1/SERCA2a; AAV1/SSERCA2a; MYDICAR; rAAV1-SERCA2a; SERCA2a gene therapy; SRD-001

Latest Information Update: 27 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celladon; Targeted Genetics
  • Developer Eiger BioPharmaceuticals, Inc.; Sardocor; Theragene Pharmaceuticals
  • Class Gene therapies; Heart failure therapies
  • Mechanism of Action Adenosine triphosphatase stimulants; Gene transference; Sarcoplasmic reticulum calcium-transporting ATPase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Heart failure
  • No development reported Pulmonary arterial hypertension; Renal failure
  • Discontinued Urinary incontinence

Most Recent Events

  • 01 Feb 2024 Sardocor plans a phase MUSIC-DMD I trial for Dilated cardiomyopathy in March 2024 (Intracoronary, Infusion) (NCT06224660)
  • 24 Aug 2023 Phase-I clinical trials in Heart failure (In adults, In the elderly) in USA (Intracoronary) (NCT06061549)
  • 28 Jul 2021 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA (Inhalation)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top